MSC to the rescue?

No Gravatar

We discussed late last year how the injection of stem cells seems to help heart patients recover.  Not because the stem cells are growing and rebuilding the heart.  No, they are helping because they are stimulating an immune response that helps the heart recover.

That’s the opposite problem we face when an organ transplant is provided a patient.  They need life-long administration of immunosuppressive drugs, to make sure the new organ isn’t rejected by the body.  These drugs, while precluding organ rejection, can let the patient succumb to infection- or cancer.

But, maybe there’s a better way.  Think the opposite way the injection of stem cells into the heart works.

This time, it’s mesenchymal stromal cells (MSC), often obtained from bone marrow.  They don’t really qualify as stem cells- but they can differentiate into different sorts of cells- bone, cartilage, tendons, ligaments, adipocytes, dermis, muscle, connective tissue.

Dr. Giuseppe Remuzzi (at the Mario Negri Institute for Pharmacological Research, Milan) has been involved in dialysis and transplantation for some time.  One of his current projects has involved the injection of the mesenchymal stromal cells the day before a patient received a kidney transplant.  That injection seems to be effective in toning down the body’s immune response, perhaps educating the body to live with the allograft.   (His recent paper, co-authored by Federica Casiraghi [Current Opinion in Nephrology and Hypertension], Mesenchymal stromal cells in kidney transplantation gives more information about this concept.  The rest of his team, Drs. N. Perico, M. Todeschini, M. Cortenovis, E Gotti, V. Portalupi, M. Mister, F. Gaspari, A. Villa, S. Fiori, M. Introna, E. Longhi, joined him in an earlier paper,  Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell [MSC] Immunotherapy.)

The MSC were taken from the recipient’s bone marrow and were grown in vitro (in the lab), after which they were injected back into the patient.

MSC and Kidney Transplants

The issue- at least for now- is that the cell injection only attenuates the need for immunosuppressive therapy.  Except for one patient who was able to completely discontinue the immunosuppressive therapy.  The biomarkers in his body after 2 years indicated this would be a viable process- but the protection tapered off slowly over 5 years.

But other patients did not show tolerance in their blood tests.  And, some patients have developed tolerance to organ transplants without any such injections.

Another  team of Dutch physicians, Dr. MEJ Reinders and TJ Rabelnk, with their associates Drs.  JW de Fijter, H Roelofs, IM Bajema, DK de Vries, AF Schaapherder, FHJ Claas, PPMC van Miert, DL Roelen, C van Kooten, and WE Fibbe published results about 6 patients in Holland. (The journal: Stem Cells Translational Medicine).  Here, the patients did NOT receive MSC injections pre-emptively, but only after they were experiencing allograft rejection.   The patients were injected twice,  months post-transplantation with 1-2 million MSC per kilogram of body weight.  Systemic immunosuppression was noted, but no regenerative effects from the MSC injections were found.

So, we need to learn way more about the MSC mechanistic action- plus a more complete evaluation of the biomarkers involved before we attempt to cease immunosuppressive treatments for all patients.

Here’s to hope. And, science, of course!

Roy A. Ackerman, Ph.D., E.A.

 

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
Share

10 thoughts on “MSC to the rescue?”

    1. The issue- at least for now- is that this may be wishful thinking. We scientists are just as guilty as the rest of the world at seeking one indication of success and being elated. But, unless we can find a significant portion of folks achieving success, this is way too expensive (and extensive) a process

Comments are closed.